Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 27

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 27
---
 formulation

The upcoming expiration of our current patents
may pose a risk to our ability to protect the lipid-based vaccine delivery technology in its original form. While we continue to hold
exclusive licensing rights to the existing patents through Yissum, the eventual expiration of these patents may limit our ability to
enforce claims specifically related to the CCS lipid composition. To mitigate this risk, the Company intends to pursue next-generation
intellectual property focused on novel antigen combinations, alternative immunization routes (including intranasal administration), and
indication-specific applications (use patents). Nevertheless, there can be no assurance that these new patent applications will be granted
or, if granted, that they will offer commercially meaningful protection.

<div align='center'>12</div>

We may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely affect our ability to develop certain of our product candidates and our financial condition and operating results.

A key part of our business plan is to establish
and cultivate long-term relationships with strategic partners, including collaborations with global health organizations, like WHO and
NIH, NGOs, and government health organizations. These partnerships can facilitate market access, drive adoption, and support public health
initiatives. We must successfully contract with these and other third parties to develop and market our novel technology. We are evaluating
additional potential partnerships and collaborative agreements as a way to further fund operations, but there is no assurance we will
be able to secure partnerships or other arrangements and to negotiate commercially acceptable licensing or other agreements for the future
exploitation of our novel technology, including the continued clinical development, manufacture or marketing of our novel technology.
If we are unable to successfully contract for these services, or if arrangements for these services are terminated, we may have to delay
our commercialization program for our novel technology, which will adversely affect our ability to generate operating revenues.

The success of our business operations is dependent on our ability to successfully develop our products and to complete clinical programs. We cannot assure you that we will successfully develop any products, or if we do, that they will be commercially successful.

Our ability to achieve and sustain operating
profitability depends on our ability, directly or with strategic partners, to successfully commercialize our products in Europe, Asia
and in the US. This will depend in large part on our ability to commence, execute and complete clinical programs and obtain regulatory
approvals for our products.

Clinical trials are necessary before we can seek
regulatory approval to sell our products. We cannot assure you that